GC01 is protected by three patent families WO2005121172 and WO2011073207 for which GlioCure has exclusive worldwide rights.
Depending on the targeted indication, GC01 is also eligible for orphan drug status, which confers market exclusivity for 7 to 10 years post marketing authorisation.